Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
It can be difficult to effectively treat RCC, especially in the advanced setting. Which is why it is important to identify and achieve certain goals of therapy for your patients. Nexavar has demonstrated efficacy in the treatment of advanced RCC.1,2
For more information about dosing and administration, and how Nexavar can fit seamlessly into your treatment plan, click on the Treatment Plan button.
References: 1. Stadler WM, Figlin RA, McDermott DF, et al; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280. 2. Beck J, Procopio G, Negrier S, et al. Final analysis of a large, open-label, noncomparative study of sorafenib in European patients with advanced RCC (EU-ARCCS) [poster]. Presented at: 34th ESMO Annual Congress; September 20-24, 2009; Berlin, Germany.